BioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public Offering
December 02 2021 - 8:55PM
BioPlus Acquisition Corp. (the “Company”) announced today that it
priced its upsized initial public offering of 20,000,000 units at
$10.00 per unit. The units will be listed on the Nasdaq Global
Market (“Nasdaq”) and will begin trading tomorrow, Friday, December
3, 2021, under the ticker symbol “BIOSU”. Each unit consists one of
the Company’s Class A ordinary shares and one-half of one
redeemable warrant, each whole warrant entitling the holder thereof
to purchase one of the Company’s Class A ordinary shares at a price
of $11.50 per share. Only whole warrants are exercisable and will
trade. Once the securities comprising the units begin separate
trading, the Class A ordinary shares and warrants are expected to
be listed on Nasdaq under the symbols “BIOS” and “BIOSW,”
respectively.
The Company is a blank check company incorporated for the
purpose of effecting a merger, capital stock exchange, asset
acquisition, stock purchase, reorganization or similar business
combination with one or more businesses. While the Company may
pursue an initial business combination target in any business or
industry, it intends to focus its search on companies in the life
sciences industry. The Company is led by Chief Executive Officer
and Chief Financial Officer, Ross Haghighat, and Chairman of the
Board and Chief Business Officer, Jonathan Rigby. Cantor Fitzgerald
& Co. is acting as the sole book running manager for the
offering. The Company has granted the underwriters a 45-day option
to purchase up to an additional 3,000,000 units at the initial
public offering price to cover over-allotments, if any.
The offering is being made only by means of a prospectus. Copies
of the prospectus may be obtained, when available, from Cantor
Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue,
5th Floor New York, New York 10022; Email:
prospectus@cantor.com.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission
(“SEC”) on December 2, 2021. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute
“forward-looking statements,” including with respect to the closing
of the Company’s initial public offering. No assurance can be given
that the offering discussed above will be completed on the terms
described, or at all. Forward-looking statements are subject to
numerous conditions, many of which are beyond the control of the
Company, including those set forth in the Risk Factors section of
the Company’s registration statement and preliminary prospectus for
the offering filed with the SEC. Copies are available on the SEC’s
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
Contact
Ross Haghighat Jonathan Rigby BioPlus Acquisition Corp.
info@bioplusspac.com
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Jul 2024 to Aug 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2023 to Aug 2024